Obstetrics/Gynecology articles: The New England Journal of Medicine (2 articles)

SpecialtyObstetrics/Gynecology

original article

Bevacizumab in the Treatment of Ovarian Cancer

December 29, 2011 | R.A. Burger
and Others

Incorporating bevacizumab in a chemotherapy regimen (7.5 mg/kg every 3 weeks for five or six cycles) and then continuing bevacizumab alone for a total of 12 months of treatment extended progression-free survival in advanced and high-risk earlystage ovarian cancer.

Bevacizumab in Ovarian Cancer Treatment

December 29, 2011 | T.J. Perren
and Others

The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of treatment improved progression-free survival by 4 months in incompletely resected stage III or IV ovarian cancer.